THE EFFECT OF OXYPHENBUTAZONE (TANDEARIL) ON THE LEVEL OF THE SEROMUCOID FRACTION OF RATS BEARING WALKER 256 CARCINOMA

The effect of oxyphenbutazone (Tandearil) on the seromucoid protein and seromucoid-bound carbohydrates of Walker 256 carcinoma bearing rats has been investigated. Initially, treatment is associated with increased tumor growth and suppression of the anticipated glycoprotein response in the serum. After the eighth day, tumor growth ceases in treated animals and the serum glycoproteins manifest progressive elevations which are, however, less than those observed in untreated tumor-bearing controls. The survival time of treated animals exceeded that of untreated tumor-bearing animals, and treated animals were free of gross malignant disease at the time of death.

Download Full-text

The Effect of Oral Oxyphenbutazone (Tandearil) on Tumor Growth and the Level of the Seromucoid Fraction in Rats Bearing Walker 256 Carcinoma

Canadian Journal of Physiology and Pharmacology ◽

10.1139/y71-152 ◽

1971 ◽

Vol 49 (12) ◽

pp. 1071-1077

Author(s):

R. A. L. Macbeth ◽

J. D. Fischer

Keyword(s):

Tumor Growth ◽

Malignant Disease ◽

Initial Response ◽

Male Rat ◽

Survival Times ◽

Tumor Bearing ◽

Untreated Tumor ◽

Adult Male Rat ◽

Walker 256 ◽

Dose Levels

The effect of the oral administration of oxyphenbutazone (Tandearil) on tumor growth and the levels of the seromucoid protein and seromucoid-bound carbohydrates of rats bearing Walker 256 has been studied. Oxyphenbutazone was administered at two dose levels, namely 60 mg/kg per day and 100 mg/kg per day. The anticipated elevation of seromucoid protein and seromucoid-bound carbohydrates was observed in untreated tumor-bearing rats. Oxyphenbutazone treatment suppressed the initial response of seromucoid protein and seromucoid-bound carbohydrate in tumor-bearing rats such that no significant elevation occurred over levels recorded for untreated nontumor-bearing rats for the first 8 days following transplantation. After 8 days the levels of seromucoid protein and seromucoid-bound carbohydrate were elevated in treated tumor-bearing animals as compared with untreated nontumor-bearing controls although the magnitude of the elevation was significantly less than that observed in untreated tumor-bearing animals.Oxyphenbutazone at an oral dose of 100 mg/kg per day proved toxic to the adult male rat. Toxicity was manifested by weight loss and occasionally by a fatal hemorrhagic gastritis.Tumors regressed in oxyphenbutazone-treated animals, and survival times of animals treated with oxyphenbutazone at 60 mg/kg per day exceeded those of comparable untreated tumor-bearing animals. In addition, treated animals were free of apparent malignant disease at the completion of the study.

Download Full-text

Tumor growth characteristics of the Walker 256 AR tumor, a regressive variant of the rat Walker 256 A tumor

Brazilian Archives of Biology and Technology ◽

10.1590/s1516-89132010000500014 ◽

2010 ◽

Vol 53 (5) ◽

pp. 1101-1108 ◽

Cited By ~ 2

Author(s):

Fernando Guimarães ◽

Alessandra Soares Schanoski ◽

Tereza Cristina Samico Cavalcanti ◽

Priscila Bianchi Juliano ◽

Ana Neuza Viera-Matos ◽

...

Keyword(s):

Growth Rate ◽

Tumor Growth ◽

Wistar Rats ◽

Tumor Regression ◽

Growth Characteristics ◽

Tumor Growth Rate ◽

Continuous Growth ◽

Tumor Bearing ◽

Walker 256 ◽

Complete Tumor

The present study aimed at characterizing the subcutaneous development of the Walker 256 (W256) AR tumor, a regressive variant of the rat W256 A tumor. Wistar rats were injected subcutaneously with 4x10(6) W256 A or W256 AR tumor cells. The development of tumors was evaluated daily by percutaneous measurements. None of the W256 A tumors (n=20) regressed, but 62% of the W256 AR tumor-bearing rats (n=21) underwent complete tumor regression within 35 days. Continuous growth of AR tumors was characterized by an increase of the tumor growth rate from day 12, which reached values above 1.0 g/day, and were significantly higher (p<0.05) than those of the regressive AR tumors. Immunosuppression by irradiation before subcutaneous injection of AR cells completely abrogated tumor regression and was associated with severe metastatic dissemination. Daily evaluation of the tumor growth rate enabled the discrimination, in advance, between continuously growing tumors and those that regressed later on.

Download Full-text